Takeda Raises 2024 Outlook: Now Expects Revenue Of ¥4.48T (Prior ¥4.35T) Vs. ¥4.497T Est.; And Core EPS Of ¥456 (Prior ¥431); Sees Adjusted Free Cash Flow Of ¥400B-¥500B (Prior ¥350B - ¥450B)
Takeda Pharmaceutical Company Limited TAK | 13.57 13.57 | +0.07% 0.00% Post |
Updating Full Year Management Guidance, and Reported and Core Forecasts
Takeda's FY2024 Management Guidance has been upgraded, primarily due to milder than anticipated generic erosion of VYVANSE and strong business momentum. Furthermore, also reflecting expected foreign exchange rates during the remaining second half of FY2024, Takeda's FY2024 reported and Core forecasts have been revised from the original forecast.
FY2024 Management Guidance Core Change at CER (Non-IFRS) | ||
FY2024 ORIGINAL MANAGEMENT GUIDANCE (May 2024) |
FY2024 REVISED MANAGEMENT GUIDANCE (October 2024) |
|
Core Revenue | Flat to slightly declining | Flat to slightly increasing |
Core Operating Profit | Approximately 10% decline | Mid-single-digit % decline |
Core EPS (Yen) | Mid-10s% decline | Approx 10% decline |
FY2024 Reported and Core Forecasts (Billion yen, except percentages and per share amounts) |
||
FY2024 (May 2024) |
FY2024 REVISED FORECAST (October 2024) |
|
Revenue | 4,350.0 | 4,480.0 |
Core Revenue (Non-IFRS) | 4,350.0 | 4,480.0 |
Operating Profit | 225.0 | 265.0 |
Core Operating Profit (Non-IFRS) | 1,000.0 | 1,050.0 |
Net Profit | 58.0 | 68.0 |
EPS (Yen) | 37 | 43 |
Core EPS (Yen) (Non-IFRS) | 431 | 456 |
Adjusted Free Cash Flow (Non-IFRS) | 350.0 - 450.0 | 400.0-500.0 |
Annual Dividend per Share (Yen) | 196 | 196 |